How to appeal a Regence hereditary angioedema (hae) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Regence-specific note: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.

What Regence typically denies for hereditary angioedema (hae)

Across Regence's commercial and Medicare books, denials cluster around a small number of patterns. For hereditary angioedema (hae), expect:

• Cross-state coordination for multi-state members (OR/WA/ID/UT)
• Step therapy via Prime Therapeutics
• Behavioral health network adequacy
• Specialty drug PA

Treatments most often denied in this category

These are the hereditary angioedema (hae) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Takhzyro
• Orladeyo
• Haegarda
• Cinryze
• Berinert
• Ruconest

How to submit the appeal to Regence

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Regence cited in the denial.
3. File the appeal through Regence's portal (members: https://www.regence.com ; providers: https://www.regence.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In OR, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.